Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Four-way Crossover Study to Compare the Pharmacodynamics and Pharmacokinetics of GW685698X and GW642444M When Administered Separately and in Combination as a Single Dose From a Novel Dry Powder Device in Healthy Japanese Subjects
Brief Summary: A combination of the corticosteroid GW685698X and the long-acting ß2-agonist GW642444M is being developed for once daily administration for the maintenance treatment of asthma and COPD. GW642444M and GW685698X will be simultaneously co-administered from a single device and compared with GW642444M and GW685698X administered separately in order to determine whether co-administration affects the safety, tolerability, pharmacodynamic and/or pharmacokinetics of either compound in healthy Japanese subjects.


Options:
A: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone furoate; Assigned to Arm(s): fluticasone furoate
B: Arm Label: Subjects receiving fluticasone foroate/ vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone foroate/ vilanterol, Drug: Fluticasone foroate, Drug: Vilanterol | Arm Label: Subjects receiving fluticasone foroate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone foroate | Arm Label: Subjects receiving vilanterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vilanterol | Arm Label: Subjects receiving placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone foroate/ vilanterol; Assigned to Arm(s): Subjects receiving fluticasone foroate/ vilanterol | Intervention Type: DRUG; Name: Fluticasone foroate; Assigned to Arm(s): Subjects receiving fluticasone foroate, Subjects receiving fluticasone foroate/ vilanterol | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Subjects receiving fluticasone foroate/ vilanterol, Subjects receiving vilanterol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Subjects receiving placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: inhaled corticosteroid(ICS)/long acting bronchodilator (LABA); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/Vilanterol (VI; GW642444M) | Arm Label: ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Furoate; Assigned to Arm(s): ICS | Intervention Type: DRUG; Name: FF/Vilanterol (VI; GW642444M); Assigned to Arm(s): inhaled corticosteroid(ICS)/long acting bronchodilator (LABA) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Fluticasone propionate

Answer: B